Skip to content

What Now, What Next? Appropriate Management for mUC
How I Practice Video #2: Role of Treatment Guidelines in Therapy Selection & Sequencing for mUC
*Pre-assessment*

Before you view this activity, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit. 

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.
1.What are your specialty & credentials?(Required.)
2.What is your community of practice?
3.Per NCCN guidelines, which of the following is a preferred first-line regimen for cisplatin eligible patients with mUC?(Required.)
4.Erdafitinib is recommended as a second-line treatment option for patients with which genetic alteration?(Required.)
5.75yo woman with newly diagnosed PD-L1 positive mUC has a GFR of 25mL/min. According to the EAU guidelines, which of the following would be an appropriate 1L treatment option for her?
6.A 77-year-old man with mUC and no identifiable genetic alterations receives 1L EV+P and 2L gem + cis. He presents 9 months after completing 2L treatment with progressive disease. Which of the following would be an appropriate 3L treatment for him based on NCCN guidelines?
7.Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity). 

Completing the fields below does not immediately qualify you for a CME certificate. Only after completing the post-survey & evaluation form will a certificate be issued.

*Please note that we will not forward or sell your contact information.
Privacy & Cookie Notice